Press Releases
-
CD Formulation: How to Select Pharmaceutical Excipients
Pharmaceutical excipients can be classified into natural, semi-synthetic and fully synthetic compounds according to their sources. And based on their use, excipients can be divided into diluents, binders, disintegrants, lubricants, glidants and anti-caking agents, wetting agents and solubilizers.
May 17, 2022
-
Alfa Chemistry Starts to Supply Quaternary Phosphonium Compounds for Formulation of Disinfectants and Antiseptics
Earlier this month, the New York-based chemical supplier Alfa Chemistry announces its decision to start to provide quaternary phosphonium compounds (QPCs), which proves to be effective antimicrobial scaffolds with improved broad-spectrum activities compared to commercial Quaternary Ammonium Compounds (QACs).
May 17, 2022
-
Four Well-Established Strategies Used in Hit Identification
A successful hit identification campaign relies on the use of a high-quality, diverse library of potential compounds to be screened, but also on capitalizing on other complementary techniques, such as structure-based virtual screening (SBVS) and fragment-based screening.
May 15, 2022
-
AARDEX® Group adds etectRx to their MEMS® Adherence Hardware ecosystem
AARDEX® Group adds etectRx to their MEMS® Adherence Hardware ecosystem The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor Liege, Belgium (APRIL 28th, 2022) – Belgium-based AARDEX® Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s ingestible event marker, the ID-Cap™ System, and AARDEX® Group’s MEMS® Adherence Software (MEMS AS®) to track medication-taking behaviors. Together, they provide a holistic, objective, and precise method to measure and manage adherence to solid form dose medications.
Apr 27, 2022
-
Royal seal of approval for leading resin manufacturer Purolite
Purolite, an Ecolab company and leading manufacturer of synthetic and agarose-based resins used in the bioprocessing industry, has been awarded the prestigious Queen’s Award for Enterprise in the International Trade category.
Apr 28, 2022
-
Total Peptide Library: More Flexible and Productive
Since the peptide library provides a powerful tool for drug development, protein-protein interactions, and other biochemical as well as pharmaceutical applications, the total peptide library becomes a productive tool as it enjoys higher stability because of the special structure of the peptide bond. Additionally, its construction cycle is relatively short compared with traditional peptide library construction technologies, accelerating the development of peptides drugs.
Apr 28, 2022
-
Chemical Synthesis of Peptide Drug with Solid-Phase Methodology
Peptide plays a key role in basic biochemical and physiological processes, and it is essential to many aspects of biomedical research, especially when the pharmaceutical industry continues to apply new drug candidates in the biological field. Therefore, rapid, efficient, and reliable methodology for the chemical synthesis of peptide drugs is of utmost interest in chemical biology research.
Apr 28, 2022
-
BOC Sciences Announces Featured PROTAC Design Services to Meet New Drug Discovery Goals
BOC Sciences announced featured PROTAC design services to customers around the world to meet new drug discovery goals.
Apr 28, 2022
-
PROTAC-based Methods as Traditional PROTAC Protein Degradation Technology Alternatives
Many emerging PROTAC-based technologies such as RNA-PROTACs and Photoswitchable PROTACs have expanded the scope of PROTAC development, providing more feasible potential strategies for the clinical treatment of related diseases.
Apr 28, 2022
-
Benefits of Stable Isotope Labelling in Biochemistry Research
Stable isotope labeling is a powerful technique with promising applications.
Apr 28, 2022
-
ADC Technology: A Premier Institution of Antibody-Drug Conjugates Development
ADC Technology releases a wide range of one-stop services related to ADC development such as antibody selection/modification, ADC payload and linker development, ADC conjugation, and ADC characterization and preclinical evaluation to help partners win the race of ADC research.
Apr 19, 2022
-
Elligo Health Research® Partners With Peoples Rx
Elligo Health Research and Peoples Rx Partner on Initiative to Help Share More Clinical Research Opportunities
Apr 28, 2022
-
Genovac further enhances its antibody discovery services with the ENPICOM IGX Platform
ENPICOM has announced that Genovac will use its IGX Platform for its antibody discovery workflows.
May 2, 2022
-
Scipio bioscience Announces Its Revolutionary Asteria© Single-cell RNA-seq Kit and Companion Cytonaut© Analysis Software Are Now Commercially Available
Scipio bioscience has announced that Asteria©, the latest breakthrough single-cell RNA-sequencing kit, is now commercially available for any researcher worldwide.
May 2, 2022
-
Matica Bio Opens New Cell and Gene Therapy GMP Facility in Texas
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
May 2, 2022
-
CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development
CYTENA has entered a collaboration agreement with ExcellGene SA, a leading biologics CDMO that manufactures recombinant proteins.
May 2, 2022
-
Biotium Announces Acquisition of CAT5™ FFPE RNA/DNA Extraction Technology from Cell Data Sciences
Biotium is announcing the acquisition of Cell Data Sciences RNAstorm™ and DNAstorm™ kits for RNA/DNA extraction.
May 2, 2022
-
RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, today announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas (UT) Southwestern in Dallas.
May 2, 2022
-
Creative Bioarray Provides Expertise in Delivering Comprehensive Pain Models to Support Pain Studies
-
Creative Bioarray Supplies Comprehensive Products to Support The Needs of Cell Culture Applications